Payment overview · 2025
General Payments
$626.99
26 reported records · 9 companies
Healthcare provider profile · identity verified
Atta Butt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAFETY HARBOR, FL · NPI 1083727317
Verified facts
What the public records show
CMS Open Payments records show Atta Butt, MD received $626.99 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.35 | 27.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.03 | 23.9% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $127.24 | 20.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.50 | 7.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.31 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.85 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.26 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.08 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.37 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $626.99 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $150.03 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.81 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $90.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.54 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $36.95 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 244 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 263 |
| Levothyroxine Sodium | Levothyroxine Sodium | 757 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 702 | 224 |
| Lisinopril | Lisinopril | 520 | 158 |
| Losartan Potassium | Losartan Potassium | 515 | 158 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 159 |
| Alprazolam | Alprazolam | 452 | 102 |
| Prednisone | Prednisone | 422 | 216 |
| Metoprolol Tartrate | Metoprolol Tartrate | 386 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 114 |
| Furosemide | Furosemide | 361 | 122 |
| Escitalopram Oxalate | Escitalopram Oxalate | 337 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 332 | 108 |
| Omeprazole | Omeprazole | 305 | 94 |
| Metformin Hcl | Metformin Hcl | 304 | 103 |
| Clopidogrel | Clopidogrel Bisulfate | 293 | 83 |
| Methylprednisolone | Methylprednisolone | 275 | 198 |
| Simvastatin | Simvastatin | 255 | 79 |
| Azithromycin | Azithromycin | 253 | 194 |
| Eliquis | Apixaban | 244 | 52 |
| Gabapentin | Gabapentin | 233 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 209 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 67 |
| Carvedilol | Carvedilol | 200 | 62 |
| Trazodone Hcl | Trazodone Hcl | 192 | 65 |
| Glipizide | Glipizide | 170 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 170 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 55 |
| Temazepam | Temazepam | 162 | 33 |
| Famotidine | Famotidine | 154 | 50 |
| Montelukast Sodium | Montelukast Sodium | 154 | 54 |
| Allopurinol | Allopurinol | 148 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 148 | 112 |
| Metformin Hcl Er | Metformin Hcl | 147 | 51 |
| Spironolactone | Spironolactone | 131 | 51 |
| Glimepiride | Glimepiride | 121 | 36 |
| Sertraline Hcl | Sertraline Hcl | 121 | 35 |
| Finasteride | Finasteride | 119 | 37 |
| Tramadol Hcl | Tramadol Hcl | 110 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 25 |
| Meclizine Hcl | Meclizine Hcl | 104 | 48 |
| Alendronate Sodium | Alendronate Sodium | 101 | 28 |
| Cephalexin | Cephalexin | 101 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 41 |
| Xarelto | Rivaroxaban | 92 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 65 |
| Donepezil Hcl | Donepezil Hcl | 82 | 26 |
| Acyclovir | Acyclovir | 81 | 33 |
| Clonazepam | Clonazepam | 80 | 12 |
| Lorazepam | Lorazepam | 79 | 11 |
| Ezetimibe | Ezetimibe | 78 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 27 |
| Atenolol | Atenolol | 75 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Baclofen | Baclofen | 69 | 42 |
| Meloxicam | Meloxicam | 67 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 39 |
| Metronidazole | Metronidazole | 60 | 42 |
| Amoxicillin | Amoxicillin | 59 | 50 |
| Venlafaxine Hcl | Venlafaxine Hcl | 59 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 17 |
| Potassium Chloride | Potassium Chloride | 58 | 21 |
| Warfarin Sodium | Warfarin Sodium | 57 | 15 |
| Nitroglycerin | Nitroglycerin | 56 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 42 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 13 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Mirtazapine | Mirtazapine | 52 | 22 |
| Farxiga | Dapagliflozin Propanediol | 50 | 18 |
| Terazosin Hcl | Terazosin Hcl | 50 | 16 |
| Folic Acid | Folic Acid | 47 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Memantine Hcl | Memantine Hcl | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 14 |
| Topiramate | Topiramate | 46 | 11 |
| Levofloxacin | Levofloxacin | 41 | 29 |
| Buspirone Hcl | Buspirone Hcl | 39 | 17 |
| Ibuprofen | Ibuprofen | 39 | 17 |
| Lovastatin | Lovastatin | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 13 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 31 |
| Tadalafil | Tadalafil | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 30 |
| Celecoxib | Celecoxib | 37 | 13 |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 16 |
| Gentamicin Sulfate | Gentamicin Sulfate | 34 | 25 |
| Mupirocin | Mupirocin | 34 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 29 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 19 |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 11 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | 14 |
| Colchicine | Colchicine | 23 | 11 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 13 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Estradiol | Estradiol | 22 | 12 |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 13 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Benzonatate | Benzonatate | 13 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 11 |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $626.99 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, KRYSTEXXA, OTEZLA, REPATHA, TRELEGY ELLIPTA, VRAYLAR, WATCHMAN Access System, WATCHMAN FLX, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error